Macrogenics (NASDAQ: MGNX)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-07-28 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.860 | -1.080 | -0.2200 | ||||
REV | 21.480M | 11.101M | -10.379M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Macrogenics (NASDAQ: MGNX) through any online brokerage.
Other companies in Macrogenics’s space includes: Impel Pharmaceuticals (NASDAQ:IMPL), Vaxxinity (NASDAQ:VAXX), Inozyme Pharma (NASDAQ:INZY), MoonLake (NASDAQ:MLTX) and Gritstone Bio (NASDAQ:GRTS).
The latest price target for Macrogenics (NASDAQ: MGNX) was reported by Guggenheim on Thursday, May 5, 2022. The analyst firm set a price target for 0.00 expecting MGNX to fall to within 12 months (a possible -100.00% downside). 10 analyst firms have reported ratings in the last year.
The stock price for Macrogenics (NASDAQ: MGNX) is $3.02 last updated June 29, 2022, 8:00 PM UTC.
There are no upcoming dividends for Macrogenics.
Macrogenics’s Q2 earnings are confirmed for Thursday, July 28, 2022.
There is no upcoming split for Macrogenics.
Macrogenics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.